234 related articles for article (PubMed ID: 35842190)
21. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
22. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
Chow SC; Lam PY; Lam WC; Fung NSK
Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.
Stahl A; Nakanishi H; Lepore D; Wu WC; Azuma N; Jacas C; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Leal S; Schlief S; Schmelter T; Miller T; Köfüncü E; Fielder A;
JAMA Netw Open; 2024 Apr; 7(4):e248383. PubMed ID: 38687481
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
[TBL] [Abstract][Full Text] [Related]
25. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
27. New trends in intravitreal anti-VEGF therapy for ROP.
Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
[TBL] [Abstract][Full Text] [Related]
28. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
29. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial.
Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR;
Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
31. The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis.
Hoyek S; Peacker BL; Acaba-Berrocal LA; Al-Khersan H; Zhao Y; Hartnett ME; Berrocal AM; Patel NA
JAMA Ophthalmol; 2022 Nov; 140(11):1110-1120. PubMed ID: 36201195
[TBL] [Abstract][Full Text] [Related]
32. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
33. Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021.
Winter K; Pfeil JM; Engmann H; Aisenbrey S; Lorenz B; Hufendiek K; Breuss H; Khattab M; Süsskind D; Kakkassery V; Lagrèze WA; Barth T; Liegl R; Bründer MC; Skevas C; Goldammer I; Glitz B; Michalewicz E; Krohne TU; Bartmann IR; Stahl A;
Acta Ophthalmol; 2024 May; 102(3):e314-e321. PubMed ID: 37725047
[TBL] [Abstract][Full Text] [Related]
34. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis.
Nanji K; Sarohia GS; Kennedy K; Ceyhan T; McKechnie T; Phillips M; Devji T; Thabane L; Kaiser P; Sarraf D; Garg SJ; Sivaprasad S; Wykoff CC; Bakri SJ; Sheidow T; Bhandari M; Chaudhary V
Ophthalmology; 2022 May; 129(5):498-508. PubMed ID: 34871637
[TBL] [Abstract][Full Text] [Related]
35. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
37. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
[TBL] [Abstract][Full Text] [Related]
38. Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis.
Jiang S; Li X; Fu M; Huanglu D; Huang J; Huang W; Hu P
Int J Clin Pharm; 2023 Dec; 45(6):1317-1325. PubMed ID: 37204617
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Taher NO; Ghaddaf AA; Al-Ghamdi SA; Homsi JJ; Al-Harbi BJ; Alomari LK; Almarzouki HS
Front Med (Lausanne); 2022; 9():884608. PubMed ID: 35615084
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
